About this trial
To evaluate the safety and efficacy of reformulated raltegravir 1200 mg once daily in combination with TRUVADA™ versus raltegravir 400 mg twice daily in combination with TRUVADA™ in people with HIV who have not taken treatment before.
Raltegravir is a highly effective and well tolerated HIV treatment. It is currently approved for the treatment of HIV at a dose of 400mg twice a day when taken in combination with other HIV treatments.
Some people take Raltegravir once daily after they have become undetectable, as some people prefer to take their treatment once a day.
This study will establish the safety and effectiveness of starting treatment with at a higher dose of Raltegravir